Institut Bergonié
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1923-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.bergonie.org
Clinical Trials
135
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (95 trials with phase data)• Click on a phase to view related trials
Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma
- Conditions
- Pancreas Cancer
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 50
- Registration Number
- NCT06705335
Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
- Conditions
- Prostate CancerMetastasis
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 50
- Registration Number
- NCT06700057
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
Deep Learning for Histopathological Classification and Prognostication of Gynaecologic Smooth Muscle Tumours
- Conditions
- Stump
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 392
- Registration Number
- NCT06540846
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
- Conditions
- Adult Soft Tissue SarcomaBiliary Tract CancerNon Small Cell Lung CancerColorectal CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 120
- Registration Number
- NCT06084689
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Georges François Leclerc, Dijon, France
🇫🇷Centre Oscar Lambret, Lille, France
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 102
- Registration Number
- NCT05888857
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 24
- Next
News
Darolutamide Falls Short in Phase II Trial for AR-Positive Triple-Negative Breast Cancer
French phase II trial reveals darolutamide failed to meet its primary endpoint of 40% clinical benefit rate in AR-positive triple-negative breast cancer patients at 16 weeks.
T-DXd-Pembrolizumab Combination Shows Promise in HER2-Positive NSCLC with 80% Response Rate in First-Line Setting
A phase 1b study reveals that combining trastuzumab deruxtecan (T-DXd) with pembrolizumab demonstrates significant antitumor activity in HER2-expressing and HER2-mutant non-small cell lung cancer. The combination achieved particularly impressive results in previously untreated patients, with response rates of 62.5% and 80% in HER2-expressing and HER2-mutant NSCLC respectively.
Mendus Reports Promising Long-Term Survival Data for Vididencel in Acute Myeloid Leukemia
Mendus presented data from the ADVANCE II Phase 2 trial showing that all AML patients with confirmed tumor antigen-specific T cell responses following vididencel treatment remained alive in long-term follow-up.